Other relevant information about the company follows: The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent. Required: Answer the following questions given the information above  Calculate to the following for Pharmos considering its tax rate of 25%: i. Total Market Value for the Firm ii. After-tax cost of Loan NO EXCEL SPREADSHEETS SHOW FULL WORKINGS WITHOUT EXCEL

Intermediate Financial Management (MindTap Course List)
13th Edition
ISBN:9781337395083
Author:Eugene F. Brigham, Phillip R. Daves
Publisher:Eugene F. Brigham, Phillip R. Daves
Chapter13: Capital Budgeting: Estimating Cash Flows And Analyzing Risk
Section: Chapter Questions
Problem 1P: Talbot Industries is considering launching a new product. The new manufacturing equipment will cost...
icon
Related questions
Question

Other relevant information about the company follows:

The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent.

Required: Answer the following questions given the information above

 Calculate to the following for Pharmos considering its tax rate of 25%:
i. Total Market Value for the Firm
ii. After-tax cost of Loan

NO EXCEL SPREADSHEETS

SHOW FULL WORKINGS WITHOUT EXCEL

Pharmos Incorporated is a Pharmaceutical Company which is considering investing in a new
production line of portable electrocardiogram (ECG) machines for its clients who suffer from
cardiovascular diseases. The company must invest in equipment which cost $2,500,000 and falls
within a MARCS depreciation of 5-years and is expected to have a scrape value of $200,000 at|
the end of the project. Other than the equipment, the company needs to increase its cash and
cash equivalents by $100,000, increase the level of inventory by $30,000, increase accounts
receivable by $250,000 and increase account payable by $50,000 at the beginning of the
project. Pharmos Incorporated expect the project to have a life of five years. The company
would have to pay for transportation and installation of the equipment which has an invoice
price of $450,000o.
The company has already invested $75,000 in Research and Development and therefore
expects a positive impact on the demand for the new product line. Expected annual sales for
the ECG machines in the first three years are $1,200,000 and $850,000 in the following two
years. The variable costs of production are projected to be $267,000 per year in years one to
three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of
the project.
The introduction of the new line of portable ECG machines will cause a net decrease of $50,000
in profit, EACH YEAR in contribution after taxes, due to a decrease in sales of the other lines of
tester machines produced by the company. By investing in the new product line Pharmos
Incorporated would have to use a packaging machine which the company already has and will
be sold at the end of the project for $350,000 after-tax in the equipment market.
Transcribed Image Text:Pharmos Incorporated is a Pharmaceutical Company which is considering investing in a new production line of portable electrocardiogram (ECG) machines for its clients who suffer from cardiovascular diseases. The company must invest in equipment which cost $2,500,000 and falls within a MARCS depreciation of 5-years and is expected to have a scrape value of $200,000 at| the end of the project. Other than the equipment, the company needs to increase its cash and cash equivalents by $100,000, increase the level of inventory by $30,000, increase accounts receivable by $250,000 and increase account payable by $50,000 at the beginning of the project. Pharmos Incorporated expect the project to have a life of five years. The company would have to pay for transportation and installation of the equipment which has an invoice price of $450,000o. The company has already invested $75,000 in Research and Development and therefore expects a positive impact on the demand for the new product line. Expected annual sales for the ECG machines in the first three years are $1,200,000 and $850,000 in the following two years. The variable costs of production are projected to be $267,000 per year in years one to three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of the project. The introduction of the new line of portable ECG machines will cause a net decrease of $50,000 in profit, EACH YEAR in contribution after taxes, due to a decrease in sales of the other lines of tester machines produced by the company. By investing in the new product line Pharmos Incorporated would have to use a packaging machine which the company already has and will be sold at the end of the project for $350,000 after-tax in the equipment market.
The company will contract a new loan in the sum of $2,000,000 that is secured by
machinery and the loan has an interest rate of 6 percent. Pharmos Incorporated has also
issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually, and
matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2
percent per issue.
The company's preferred stock pays an annual dividend of 4.5 percent and is currently
selling for $60, and there are 100,000 shares outstanding.
• There are 300,000 shares of common stock outstanding, and they are currently selling
for $21 each. The beta on these shares is 0.95.
Transcribed Image Text:The company will contract a new loan in the sum of $2,000,000 that is secured by machinery and the loan has an interest rate of 6 percent. Pharmos Incorporated has also issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually, and matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2 percent per issue. The company's preferred stock pays an annual dividend of 4.5 percent and is currently selling for $60, and there are 100,000 shares outstanding. • There are 300,000 shares of common stock outstanding, and they are currently selling for $21 each. The beta on these shares is 0.95.
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 3 steps with 3 images

Blurred answer
Knowledge Booster
Rate Of Return
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.
Similar questions
Recommended textbooks for you
Intermediate Financial Management (MindTap Course…
Intermediate Financial Management (MindTap Course…
Finance
ISBN:
9781337395083
Author:
Eugene F. Brigham, Phillip R. Daves
Publisher:
Cengage Learning
Financial Management: Theory & Practice
Financial Management: Theory & Practice
Finance
ISBN:
9781337909730
Author:
Brigham
Publisher:
Cengage
Corporate Fin Focused Approach
Corporate Fin Focused Approach
Finance
ISBN:
9781285660516
Author:
EHRHARDT
Publisher:
Cengage
Excel Applications for Accounting Principles
Excel Applications for Accounting Principles
Accounting
ISBN:
9781111581565
Author:
Gaylord N. Smith
Publisher:
Cengage Learning
Fundamentals Of Financial Management, Concise Edi…
Fundamentals Of Financial Management, Concise Edi…
Finance
ISBN:
9781337902571
Author:
Eugene F. Brigham, Joel F. Houston
Publisher:
Cengage Learning
EBK CONTEMPORARY FINANCIAL MANAGEMENT
EBK CONTEMPORARY FINANCIAL MANAGEMENT
Finance
ISBN:
9781337514835
Author:
MOYER
Publisher:
CENGAGE LEARNING - CONSIGNMENT